Drug eluting injectable biomaterials for next generation chemoembolization
用于下一代化疗栓塞的药物洗脱可注射生物材料
基本信息
- 批准号:10397659
- 负责人:
- 金额:$ 65.04万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-05-01 至 2026-04-30
- 项目状态:未结题
- 来源:
- 关键词:Animal ModelApoptosisBiocompatible MaterialsBiomedical EngineeringBlood VesselsCathetersCell Cycle InhibitionCell DeathCessation of lifeChemoembolizationCoupledDataDevelopmentDoseDoxorubicinDrug ControlsDrug Delivery SystemsDrug KineticsEngineeringEuropeEvaluationFluoroscopyFormulationGelGelatinGoalsHepaticHistologyHydrogelsImageImmune checkpoint inhibitorImmunosuppressionImmunotherapeutic agentImmunotherapyIn VitroInflammatory ResponseInjectableIschemiaLiverLiver neoplasmsMalignant NeoplasmsMalignant neoplasm of liverMediatingModelingModulusMolecularOncolytic virusesOryctolagus cuniculusPatientsPenetrationPerformancePersonsPharmaceutical PreparationsPrimary carcinoma of the liver cellsProceduresPropertyPublic HealthRiskRoentgen RaysSafetySolidSolid NeoplasmSurvival RateTechnologyTestingTherapeuticTherapeutic EmbolizationThinnessTimeTissuesToxic effectTravelUnited StatesVirus DiseasesViscosityWorld Health Organizationanti-CTLA4anti-canceranti-tumor immune responsebasecancer cellcancer therapychemotherapychimeric antigen receptor T cellsdrug distributionimprovedin vivoin vivo evaluationliquid chromatography mass spectrometryliver cancer modelliver cancer patientliver transplantationneoplastic cellnext generationnovelnovel therapeuticspreventprogrammed cell death ligand 1programmed cell death protein 1side effectsuccesstumortumor ablationtumor progressionultrasound
项目摘要
Abstract
Hepatocellular carcinoma (HCC), the most common type of liver cancer, is a major worldwide public health
concern because it is often detected at advanced stages where treatment options are limited. According to the
World Health Organization, each year there are ~750,000 new HCC cases resulting in 700,000 deaths
worldwide. While historically systemic chemotherapy has been the cornerstone to cancer treatment, inability to
achieve uniform drug delivery to tumors, collateral toxicity to the non-cancerous liver and systemic side-effects
have limited progress in the development of novel therapies for liver cancer. Recently, novel
immunotherapeutic agents (immune checkpoint inhibitors (ICI), CAR-T cells, oncolytic virus) have been
developed, but there are still limitations to their use due to systemic side effects and difficulty to deliver to solid
tumors. Although transcatheter arterial chemoembolization (TACE), a procedure performed using an X-ray
guided catheter to deliver chemotherapy coupled to embolization beads into the blood vessels that perfuse the
liver tumor has shown success in liver cancer management, the embolization efficiency is relatively low as the
beads cannot be readily delivered into downstream microvasculature to achieve uniform ischemia and
chemotherapy delivery. Here we propose a transformative technology that uses a catheter-based locoregional
approach to deliver X-ray visible bioengineered biomaterial, i.e. next-generation TACE, to induce a more
efficient ischemic cell death within the tumor microvasculature coupled with efficient chemo- and
immunotherapy delivery. We aim to combine TACE with both chemo- and immuno-therapeutics (e.g. ICIs) in
order to enhance the anti-tumor immune response. Maintaining and even enhancing the inflammatory
response induced after chemotherapy may potentially yield improved tumor regression assisted by localized
ICI delivery. To achieve this goal we will mix doxorubicin (DOX) and / ICI (α-PD1, α-PDL1, α-CTLA-4) within an
injectable shear-thinning hydrogel (STH) to enhance tumor ablation. We hypothesize that STH, a semi-solid
gel like embolic material, which is composed of gelatin and nanosilicate, will achieve more efficient
endovascular embolization reaching vessels as small as 50 microns than the current TACE beads.
Simultaneously, DOX/ICI delivery will be used to locally ablate the liver cancer cells. Our preliminary data
demonstrates exciting results showing our ability to synthesize and deliver STHs using catheters, to release
drugs controllably from STHs, as well as in vitro and rabbit liver cancer models. In Aim 1, we will optimize STH
compositions for effective endovascular chemoembolization. In Aim 2, we will develop the novel drug-eluting
STH (DESTH) for endovascular Immuno-chemoembolization. In Aim 3 we will evaluate the in vivo performance
of the DESTH.
摘要
肝细胞癌是最常见的一种肝癌,是世界范围内的主要公共卫生问题
令人担忧的是,它通常在治疗选择有限的晚期被发现。根据
世界卫生组织,每年新增约75万例肝细胞癌病例,导致70万人死亡
全世界。虽然从历史上看,全身化疗一直是癌症治疗的基石,但无法
实现对肿瘤的均匀给药、对非癌肝脏的副作用和全身副作用
在开发治疗肝癌的新疗法方面进展有限。最近,小说
免疫治疗药物(免疫检查点抑制物(ICI)、CAR-T细胞、溶瘤病毒)
已开发,但由于系统性副作用和难以传递到Solid,它们的使用仍然受到限制
肿瘤。尽管经导管动脉化疗栓塞术(TACE),一种使用X射线进行的程序
引导导管将化疗与栓塞珠耦合输送到血管中,这些血管灌流
肝肿瘤在肝癌治疗中已显示出成功,但由于肝肿瘤的栓塞效率较低
珠子不容易被输送到下游的微血管系统,以实现均匀的缺血和
化疗快递。在这里,我们提出了一种变革性的技术,它使用基于导管的局部定位
提供X射线可见生物工程材料的方法,即下一代TACE,以诱导更多
肿瘤微血管内有效的缺血细胞死亡与有效的化疗和
提供免疫治疗服务。我们的目标是将TACE与化疗和免疫治疗(例如ICIS)相结合
以增强抗肿瘤免疫反应。维持甚至增强炎性
化疗后的反应可能会在局部治疗的帮助下改善肿瘤的消退
ICI快递。为了实现这一目标,我们将把阿霉素(DOX)和/ICI(α-PD1,α-PDL1,α-CTLA-4)混合在一个
可注射剪切稀释水凝胶(STH),以加强肿瘤消融。我们假设STH,一种半固体
由明胶和纳米硅酸盐组成的胶状栓塞剂将达到更有效的治疗效果。
血管内栓塞术可以到达比目前的TACE微珠小到50微米的血管。
同时,DOX/ICI传递将被用于局部消融肝癌细胞。我们的初步数据
展示了令人兴奋的结果,显示了我们使用导管合成和传递STH的能力,以释放
来自STH的可控药物,以及体外和兔肝癌模型。在目标1中,我们将优化STH
有效血管内化疗栓塞术的组合物。在目标2中,我们将开发新型药物洗脱
血管内免疫化疗栓塞术。在目标3中,我们将评估体内性能
是DESTH的。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ali Khademhosseini其他文献
Ali Khademhosseini的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ali Khademhosseini', 18)}}的其他基金
Healing enterocutaneous fistulas using bioengineered biomaterials
使用生物工程生物材料治愈肠皮瘘
- 批准号:
10384769 - 财政年份:2021
- 资助金额:
$ 65.04万 - 项目类别:
Drug eluting injectable biomaterials for next generation chemoembolization
用于下一代化疗栓塞的药物洗脱可注射生物材料
- 批准号:
10620134 - 财政年份:2021
- 资助金额:
$ 65.04万 - 项目类别:
Drug eluting injectable biomaterials for next generation chemoembolization
用于下一代化疗栓塞的药物洗脱可注射生物材料
- 批准号:
10230909 - 财政年份:2021
- 资助金额:
$ 65.04万 - 项目类别:
Healing enterocutaneous fistulas using bioengineered biomaterials
使用生物工程生物材料治愈肠皮瘘
- 批准号:
10532787 - 财政年份:2021
- 资助金额:
$ 65.04万 - 项目类别:
Treatment of arterial aneurysms using an injectable biomaterial
使用可注射生物材料治疗动脉瘤
- 批准号:
10171610 - 财政年份:2018
- 资助金额:
$ 65.04万 - 项目类别:
Treatment of arterial aneurysms using an injectable biomaterial
使用可注射生物材料治疗动脉瘤
- 批准号:
9883832 - 财政年份:2018
- 资助金额:
$ 65.04万 - 项目类别:
Engineering personalized micro-tumor ecosystems
设计个性化微肿瘤生态系统
- 批准号:
10261573 - 财政年份:2017
- 资助金额:
$ 65.04万 - 项目类别:
相似国自然基金
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
- 批准号:LBY21H010001
- 批准年份:2020
- 资助金额:0.0 万元
- 项目类别:省市级项目
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
- 批准号:81703335
- 批准年份:2017
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
- 批准号:81670594
- 批准年份:2016
- 资助金额:58.0 万元
- 项目类别:面上项目
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
- 批准号:81470791
- 批准年份:2014
- 资助金额:73.0 万元
- 项目类别:面上项目
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
- 批准号:81301123
- 批准年份:2013
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
- 批准号:81101529
- 批准年份:2011
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
- 批准号:39500043
- 批准年份:1995
- 资助金额:9.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Milk fat globule-EGF factor 8 and hepatocyte apoptosis-induced liver wound healing response
乳脂肪球-EGF因子8与肝细胞凋亡诱导的肝脏创面愈合反应
- 批准号:
10585802 - 财政年份:2023
- 资助金额:
$ 65.04万 - 项目类别:
Development of an apoptosis biosensor for monitoring of breast cancer
开发用于监测乳腺癌的细胞凋亡生物传感器
- 批准号:
10719415 - 财政年份:2023
- 资助金额:
$ 65.04万 - 项目类别:
Interrogating the Fgl2-FcγRIIB axis on CD8+ T cells: A novel mechanism mediating apoptosis of tumor-specific memory CD8+ T cells
询问 CD8 T 细胞上的 Fgl2-FcγRIIB 轴:介导肿瘤特异性记忆 CD8 T 细胞凋亡的新机制
- 批准号:
10605856 - 财政年份:2023
- 资助金额:
$ 65.04万 - 项目类别:
Novel targeted therapy for FGFR inhibitor-resistant urothelial cancer and apoptosis based therapy for urothelial cancer
FGFR抑制剂耐药性尿路上皮癌的新型靶向治疗和基于细胞凋亡的尿路上皮癌治疗
- 批准号:
23K08773 - 财政年份:2023
- 资助金额:
$ 65.04万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Mechanistic analysis of apoptosis induction by HDAC inhibitors in head and neck cancer
HDAC抑制剂诱导头颈癌凋亡的机制分析
- 批准号:
23K15866 - 财政年份:2023
- 资助金额:
$ 65.04万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Interrogating the Fgl2-FcgRIIB axis: A novel mechanism mediating apoptosis of tumor-specific memory CD8+ T cells
探究 Fgl2-FcgRIIB 轴:介导肿瘤特异性记忆 CD8 T 细胞凋亡的新机制
- 批准号:
10743485 - 财政年份:2023
- 资助金额:
$ 65.04万 - 项目类别:
Investigating the role of apoptosis-resistance and the tumor environment on development and maintenance of sacrococcygeal teratomas
研究细胞凋亡抗性和肿瘤环境对骶尾部畸胎瘤发生和维持的作用
- 批准号:
10749797 - 财政年份:2023
- 资助金额:
$ 65.04万 - 项目类别:
The effects of glucose on immune cell apoptosis and mitochondrial membrane potential and the analysis of its mechanism by which glucose might modulate the immune functions.
葡萄糖对免疫细胞凋亡和线粒体膜电位的影响及其调节免疫功能的机制分析。
- 批准号:
22K09076 - 财政年份:2022
- 资助金额:
$ 65.04万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
XAF1 IN P53 SIGNALING, APOPTOSIS AND TUMOR SUPPRESSION
P53 信号传导、细胞凋亡和肿瘤抑制中的 XAF1
- 批准号:
10583516 - 财政年份:2022
- 资助金额:
$ 65.04万 - 项目类别:
Role of Thioredoxin system in regulation of autophagy-apoptosis cross talk in neurons: Uncovering Novel Molecular Interactions.
硫氧还蛋白系统在神经元自噬-凋亡串扰调节中的作用:揭示新的分子相互作用。
- 批准号:
RGPIN-2019-05371 - 财政年份:2022
- 资助金额:
$ 65.04万 - 项目类别:
Discovery Grants Program - Individual